https://www.bostonglobe.com/business/2015/10/21/biogen-cut-percent-workforce-restructuring/lFwneNSEf6W8Xa3WdJE2QJ/story.html
It’s the world’s largest maker of multiple sclerosis drugs and the
most highly valued company in Massachusetts. But size and status
couldn’t shield Biogen Inc. from stumbling in the notoriously risky
biotechnology business.
On Wednesday, Biogen said that it will cut
about 880 jobs, including 400 in its home state, and end several
research programs in a restructuring driven by slower sales growth and a
multiple sclerosis drug trial that fell short of expectations.
The layoffs will eliminate 11 percent of the Cambridge company’s 8,000-person worldwide workforce.
No comments:
Post a Comment